NCT00263653 - Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 | Biotech Hunter

Enrollment

297

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

March 31, 2005

Study Completion Date

September 30, 2005

Conditions

Haemophilus Influenzae Type bNeisseria Meningitidis

Interventions

BIOLOGICAL

Haemophilus influenzae type b- and meningococcal (vaccine)

Trial Locations (16)

GSK Investigational Site, Lleida

GSK Investigational Site, Aravaca

GSK Investigational Site, Madrid

GSK Investigational Site, Madrid

GSK Investigational Site, Antequera/Málaga

GSK Investigational Site, Marbella

GSK Investigational Site, Pamplona

GSK Investigational Site, Seville

GSK Investigational Site, Almería

GSK Investigational Site, Almería

GSK Investigational Site, Blanes

GSK Investigational Site, Vélez-Málaga

GSK Investigational Site, Burgos

GSK Investigational Site, Mollet Del Valles/Barcelona

GSK Investigational Site, Sant Adriá de Beyós, Barcelona

GSK Investigational Site, Sant Eugenia de Berga, Barcelona